Ramipril in High-Risk Patients With COVID-19.

ABSTRACT:

Background

Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory-syndrome coronavirus-2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2. This interaction has been proposed as a potential risk factor in patients treated with RAAS inhibitors.

Objectives

This study analyzed whether RAAS inhibitors modify the risk for COVID-19.

Methods

The RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial is an ongoing randomized clinical trial randomly allocating subjects to ramipril or control groups after successful transcatheter aortic valve replacement at 14 centers in Spain. A non-pre-specified interi

SUBMITTER: Amat-Santos IJ 

PROVIDER: S-EPMC7250557 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature